C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 84 filers reported holding C4 THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,420,859 | +419.0% | 2,376,806 | +667.3% | 0.05% | +500.0% |
| Q2 2023 | $851,826 | -95.7% | 309,755 | -95.1% | 0.01% | -96.1% |
| Q1 2023 | $20,035,963 | -41.5% | 6,380,880 | +10.0% | 0.23% | -44.3% |
| Q4 2022 | $34,236,939 | -23.3% | 5,802,871 | +14.0% | 0.41% | -25.4% |
| Q3 2022 | $44,657,000 | +1.4% | 5,091,975 | -12.8% | 0.55% | +8.7% |
| Q2 2022 | $44,052,000 | -4.9% | 5,842,407 | +206.0% | 0.50% | +24.4% |
| Q1 2022 | $46,313,000 | -18.9% | 1,909,023 | +7.6% | 0.40% | -11.6% |
| Q4 2021 | $57,139,000 | -15.6% | 1,774,504 | +17.2% | 0.46% | -13.4% |
| Q3 2021 | $67,673,000 | +28.1% | 1,514,620 | +8.5% | 0.53% | +32.9% |
| Q2 2021 | $52,810,000 | +467.4% | 1,395,621 | +454.7% | 0.40% | +468.6% |
| Q1 2021 | $9,307,000 | +12.8% | 251,617 | +1.0% | 0.07% | +9.4% |
| Q4 2020 | $8,254,000 | – | 249,149 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |